Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

BACKGROUND: In AFFIRM-AHF, treatment of iron deficiency with intravenous ferric carboxymaltose (FCM) reduced the risk of heart failure (HF) hospitalization and improved quality of life (QoL) vs placebo in patients stabilized following an acute HF (AHF) episode, with no effect on cardiovascular (CV)...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosano, Giuseppe, Ponikowski, Piotr, Vitale, Cristiana, Anker, Stefan D., Butler, Javed, Fabien, Vincent, Filippatos, Gerasimos, Kirwan, Bridget-Anne, Macdougall, Iain C., Metra, Marco, Ruschitzka, Frank, Kumpeson, Vasuki, Goehring, Udo-Michael, van der Meer, Peter, Jankowska, Ewa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436432/
https://www.ncbi.nlm.nih.gov/pubmed/37592272
http://dx.doi.org/10.1186/s12933-023-01943-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436432/
https://www.ncbi.nlm.nih.gov/pubmed/37592272
http://dx.doi.org/10.1186/s12933-023-01943-z

Ejemplares similares